Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA

Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

,David Szekeres ,Cochrane Meta ,Ashraf Habib ,Exchange Commission ,Company Codes ,Drug Administration ,Heron Therapeutics Inc ,Nasdaq ,Heron Therapeutics ,New Drug Application ,Cochrane Meta Analysis ,Barry Quart ,Chief Executive Officer ,Duke University ,Private Securities Litigation Reform Act ,Media Contact ,Vice President ,Chief Operating ,Resume ,Careers ,Eron Therapeutics Announces Submission Of Htx 019 Nda For The Prevention Postoperative Nausea And Vomiting To Fda ,Iospace ,Advice ,